Cancer Cachexia - Pipeline Review, H2 2016

Date: July 30, 2016
Pages: 108
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C3E6AB57F8AEN
Leaflet:

Download PDF Leaflet

Cancer Cachexia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cancer Cachexia - Pipeline Review, H2 2016’, provides an overview of the Cancer Cachexia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Cachexia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Cachexia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia
  • The report reviews pipeline therapeutics for Cancer Cachexia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cancer Cachexia therapeutics and enlists all their major and minor projects
  • The report assesses Cancer Cachexia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cancer Cachexia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Cancer Cachexia Overview
Therapeutics Development
Pipeline Products for Cancer Cachexia - Overview
Pipeline Products for Cancer Cachexia - Comparative Analysis
Cancer Cachexia - Therapeutics under Development by Companies
Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes
Cancer Cachexia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Cancer Cachexia - Products under Development by Companies
Cancer Cachexia - Products under Investigation by Universities/Institutes
Cancer Cachexia - Companies Involved in Therapeutics Development
Acacia Pharma Limited
Aeterna Zentaris Inc.
Aphios Corporation
Atara Biotherapeutics, Inc.
Eli Lilly and Company
Helsinn Healthcare S.A.
Incyte Corporation
Lakewood-Amedex Inc
Novartis AG
Obexia AG
PsiOxus Therapeutics Limited
RaQualia Pharma Inc.
Viking Therapeutics, Inc.
Cancer Cachexia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(formoterol fumarate + megestrol acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUSRM-057 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
espindolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Foxo1-nRNA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landogrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBX-1201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize Melanocortin Receptor for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cancer Cachexia - Dormant Projects
Cancer Cachexia - Discontinued Products
Cancer Cachexia - Product Development Milestones
Featured News & Press Releases
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
Dec 15, 2005: Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
Jan 10, 2005: Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cancer Cachexia, H2 2016
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2016
Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2016
Cancer Cachexia - Pipeline by Aphios Corporation, H2 2016
Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2016
Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2016
Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2016
Cancer Cachexia - Pipeline by Incyte Corporation, H2 2016
Cancer Cachexia - Pipeline by Lakewood-Amedex Inc, H2 2016
Cancer Cachexia - Pipeline by Novartis AG, H2 2016
Cancer Cachexia - Pipeline by Obexia AG, H2 2016
Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2016
Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2016
Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cancer Cachexia - Dormant Projects, H2 2016
Cancer Cachexia - Dormant Projects (Contd..1), H2 2016
Cancer Cachexia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Cancer Cachexia, H2 2016
Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Cancer Cachexia - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 113 pages
Cachexia - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 158 pages
Cachexia - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 67 pages
Cancer Cachexia - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Cancer Cachexia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: